Skip to main content

Table 1 Genotype and allele frequencies of BRCA2 -26 and p53 codon 72 polymorphisms in sporadic breast cancer patients and normal controls

From: Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53codon 72 Arg>Pro polymorphism

Genotypes

Patients

Controls

P a

P b

P c

OR (95% CI)d

 

N = 243

N = 333

    

BRCA2, exon 2, -26G>A

      

   G/G

144 (59.3%)

157 (47.1%)

  

-

1.0 (referent)

   G/A

74 (30.5%)

152 (45.6%)

  

0.0005e

0.5 (0.4–0.8)

   A/A

25 (10.3%)

24 (7.2%)

0.002, 0.116

0.001

0.677

1.1 (0.6–2.1)

   G

74.50%

70.00%

  

0.092

1.2 (1.0–1.6)

p53, exon 4, codon 72 Arg>Pro

      

   Pro/Pro

48 (19.8%)

97 (29.1%)

  

-

1.0 (referent)

   Pro/Arg

109 (44.9%)

160 (48.0%)

  

0.119

1.4 (0.9–2.1)

   Arg/Arg

86 (35.4%)

76 (22.8%)

0.210, 0.521

0.001

0.0005e

2.3 (1.4–3.6)

   Pro

42.20%

53.20%

  

0.0002e

0.6 (0.5–0.8)

  1. a P value for Hardy-Weinberg equilibrium testing. b P value for 3 × 2 chi-square test of comparison of overall genotype frequencies between breast cancer patients and controls. c,d P values and corresponding age-adjusted ORs with 95% CIs for comparison of genotype frequencies between breast cancer patients and controls by logistic regression (not adjusted for age in allele frequency comparisons); the referent genotypes were considered on the basis of highest proportion of a homozygous genotype at any particular locus in the control group. e P values continue to remain significant after applying Bonferroni correction of 2 (2 single-nucleotide polymorphisms tested in a case-control group) to correct for multiple comparisons. CI, confidence interval; OR, odds ratio.